Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma,☆☆,,★★

https://doi.org/10.1016/S0091-6749(97)70028-9Get rights and content

Abstract

Local secretion of cytokines by T cells within the bronchial mucosa, with consequent selective eosinophil influx, has been implicated in the pathogenesis of bronchial asthma. The cytokine IL-13 exhibits activities (selective eosinophil vascular adhesion by very late antigen-4/vascular cell adhesion molecule-1 interaction and promotion of IgE synthesis and “TH2-type” T cell responses) that may be relevant to this process. We hypothesized that, compared with conditions in control subjects, elevated expression of messenger ribonucleic acid (mRNA) encoding IL-13 is a feature of the bronchial mucosa of both atopic (positive skin prick test result to at least one of a range of common aeroallergens) and nonatopic (negative skin prick test results and serum total IgE concentrations within the normal range) subjects with asthma. With use of a semiquantitative reverse transcriptase–polymerase chain reaction technique, we measured the quantities (relative to β-actin) of IL-13 mRNA in bronchial mucosal biopsy specimens from atopic and nonatopic subjects with asthma and atopic and nonatopic control subjects. Biopsy specimens from the subjects with asthma, whether the subjects were atopic or nonatopic, had statistically equivalent quantities of IL-13 mRNA relative to β-actin, and these quantities were significantly elevated compared with those in specimens from both the atopic and nonatopic control subjects ( p ≤ 0.02 in each case), in which the quantities of IL-13 mRNA relative to β-actin were also statistically equivalent. The quantities of IL-13 mRNA reflected the numbers of EG2+ eosinophils per unit area of submucosa in the biopsy specimens as determined by immunohistochemistry, which were statistically equivalent in the atopic and nonatopic subjects with asthma and significantly elevated as compared with those in both the atopic and nonatopic control subjects without asthma (p ≤ 0.007 in each case). Taking the subjects with asthma as a group, no correlations were observed between the quantities of IL-13 mRNA (relative to β-actin) and several measures of disease severity. These data are consistent with the hypothesis that IL-13 plays a role in the pathogenesis of both atopic and nonatopic asthma, at least partly through promoting recruitment of eosinophils to the bronchial mucosa, although other factors may be more important in regulating the severity of the disease. (J Allergy Clin Immunol 1997;99:657-65.)

Section snippets

Characterization of patients and control subjects

A total of 37 carefully clinically characterized patients and volunteers (atopic asthma, n = 10; nonatopic asthma, n = 10; atopic control without asthma, n = 9; nonatopic control without asthma, n = 8) participated in the study (Table I). Asthma was defined by one or more of the following measures: (1) a clear clinical history with current relevant symptoms, (2) evidence of >20% reversibility of the FEV1 either spontaneously or after administration of inhaled β2-agonist, and (3) a histamine PC

RESULTS

The atopic and nonatopic subjects with asthma were well matched in terms of lung function, histamine PC20, and severity of symptoms (Table I). The nonatopic subjects with asthma were significantly older than the atopic subjects with asthma and the nonatopic control subjects (Table I). The atopic subjects, whether they had asthma or not, had clearly elevated median total serum IgE concentrations as compared with the nonatopic control subjects. Interestingly, the nonatopic subjects with asthma

DISCUSSION

Our data, obtained with use of a controlled and validated RT-PCR technique, demonstrate elevated expression of mRNA encoding IL-13 in the bronchial mucosa of patients with asthma, regardless of their atopic status, as compared with that in control subjects without asthma matched for atopic status. These data are compatible with the hypothesis that IL-13 plays a role in the pathogenesis of both atopic and nonatopic asthma. As far as we are aware, these are the first data that implicate IL-13 in

Acknowledgements

We thank Dr. Adrian Minty of Sanofi Elf Bio Recherches for kindly providing IL-13 cDNA and acknowledge the invaluable assistance of Dr. Derek Cramer (Royal Brompton Hospital Lung Function Unit) and the staff of Lind ward, Royal Brompton Hospital.

References (24)

  • A Minty et al.

    Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses

    Nature

    (1993)
  • BS Bochner et al.

    IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells

    J Immunol

    (1995)
  • Cited by (0)

    From the Department of Medicine, Charing Cross Hospital, Fulham Palace Road, London, United Kingdom,c the Department of Allergy and Clinical Immunology, National Heart and Lung Institute, London, United Kingdom, a and the Asthma and Allergy Clinic, Hochgebirgsklinik Davos Wolfgang, Davos, Switzerland.b

    ☆☆

    Supported by grants from the Medical Research Council (United Kingdom); an MRC Clinician Scientist Fellowship (to CJC); and grants from the Wellcome Trust, the Institut Electricité Santé, and the Société de Pneumologie de Langue Française (to MH).

    Reprint requests: Chris J. Corrigan, MD, PhD, Department of Medicine, Charing Cross Hospital, Fulham Palace Rd., London W6 8RF, United Kingdom. *Current address: Service de Pneumologie, Hôpital Antoine Béclère, 92140 Clamart, France.

    ★★

    1/1/79345

    View full text